Search clinical trials for: GLP-1 receptor agonist

Total 9772 results

University of Mississippi Medical Center

Recruiting

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Diabetes Mellitus, Type 2 | Osteoporosis, Postmenopausal

United States
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
University of Missouri-Columbia
American Society for Metabolic and Bariatric Surgery

Recruiting

Impact GLP-1 Agonists Following Bariatric

Hypertension | Diabetes Mellitus | Metabolic Syndrome | Morbid Obesity | Obstructive Sleep Apnea of Adult

United States
Dasman Diabetes Institute

Recruiting

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Diabetes Mellitus, Type 2

Kuwait
University of Copenhagen
Gentofte Hospital, Denmark

Recruiting

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function (H-21044858)

Incretin Effect

Denmark
King's College London

Recruiting

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

Obesity | Diabetes Mellitus | Mental Health Issue

United Kingdom
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Completed

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

Diabetes Mellitus, Type 2

Italy
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Completed

Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

Glucose Metabolism Disorders

Denmark
Jose Seijas Amigo

Completed

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. (SEVERAL)

Quality of Life | Diabetes Mellitus, Type 2 | Weight Loss | Safety Issues

Spain
Zealand Pharma
Profil Institut für Stoffwechselforschung GmbH

Recruiting

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Safety and Tolerability

Germany
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Completed

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Glucose Metabolism Disorders

Denmark
Mikkel Christensen
University of Copenhagen

Completed

GIP and GLP-1 in Type 1 Diabetes

Hypoglycemia

Denmark
Rigshospitalet, Denmark

Completed

Hyperglycemia and the Extra-pancreatic Effect of Incretins

Extra-pancreatic Incretin Effect | Glucose Effectiveness

Denmark
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Type 2 Diabetes Mellitus | Susceptibility, Genetic

China
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Treating PCOS With Semaglutide vs Active Lifestyle Intervention (TEAL)

PCOS | NAFLD | Adolescent Obesity

United States
Hvidovre University Hospital

Completed

Incretin Hormone Antagonism After Bariatric Surgery (INCA-BAR)

Bariatric Surgery

Denmark
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
PegBio Co., Ltd.

Completed

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects (PB119)

Type 2 Diabetes Mellitus (T2DM)

China
PegBio Co., Ltd.

Completed

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Type 2 Diabetes Mellitus (T2DM)

China
University Hospital, Gentofte, Copenhagen

Completed

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake (GASOLIN)

Obesity | Type 2 Diabetes | Adiposity

Denmark
University of Copenhagen
Hvidovre University Hospital

Completed

Gut Hormones and Bone Remodeling in Humans (KS-2) (KS-2)

Healthy

Denmark
David D'Alessio, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Incretin Action in Physiology and Diabetes

Insulin Secretion

United States
LMC Diabetes & Endocrinology Ltd.
Novo Nordisk Canada Inc.

Completed

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Chronic Kidney Diseases | Type 2 Diabetes

Canada
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
University of Pennsylvania
Children's Hospital of Philadelphia

Recruiting

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Cystic Fibrosis | Pancreatic Insufficiency

United States
Herlev Hospital
University of Copenhagen; The Danish Medical Research Council; The Danish Diabetes...

Completed

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

Type 2 Diabetes Mellitus

Denmark
Zydus Lifesciences Limited

Completed

A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers (ZYD1)

Type 2 Diabetes Mellitus

India
University of Copenhagen
Hvidovre University Hospital

Recruiting

Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury

Spinal Cord Injuries

Denmark
Nanjing First Hospital, Nanjing Medical University

Recruiting

The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

Type 2 Diabetes Mellitus

China
Radboud University Medical Center
Rijnstate Hospital

Recruiting

Visualizing Beta Cells After Bariatric Surgery (GLP1-bar)

Type 2 Diabetes Mellitus

Netherlands
University Hospital, Gentofte, Copenhagen

Completed

Effect of GIP After a Meal in Patients With Type 2 Diabetes (GA-7)

Type2 Diabetes

Denmark
University of Chicago

Completed

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Monogenic Diabetes

United States
Turku University Hospital
Lund University

Completed

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery (GIP-PET)

Obesity | Type 2 Diabetes

Finland
Brigham and Women's Hospital

Unknown

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Diabetes Mellitus, Type 2

United States
Ludwig-Maximilians - University of Munich
German Research Foundation; Merck Sharp & Dohme LLC

Completed

Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans

Hyperglycemia

Germany
University Hospital, Gentofte, Copenhagen
University of Copenhagen; Steno Diabetes Center Copenhagen

Completed

The Effect of GIP(3-30)NH2 (GA-10)

Endocrine - Other

Denmark
Zealand Pharma

Completed

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
Hvidovre University Hospital
University of Copenhagen

Completed

Effect of RYGB on Alpha- and Beta Cell Function and Sensitivity to Incretins in Patients With Type 2 Diabetes (BETASIN)

Obesity, Morbid | Type2 Diabetes

Denmark
Centre Hospitalier Universitaire Dijon

Completed

Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging (LICAS-MR)

Type II Diabetes

France
University of Padova

Completed

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Type 2 Diabetes

Italy
University of Copenhagen
Hvidovre University Hospital

Completed

Effects of Gut Peptides on Bone Remodeling (KS-3)

Healthy

Denmark
The Affiliated Hospital of Xuzhou Medical University

Completed

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Type 2 Diabetic Nephropathy

China
University Hospital Tuebingen
Merck Sharp & Dohme LLC

Withdrawn

Characterization of Beta Cell Failure

Diabetes | Metabolic Syndrome

Germany
Second Xiangya Hospital of Central South University
Guangdong Provincial People's Hospital; The First Affiliated Hospital of Henan... and other collaborators

Recruiting

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Diabetes Mellitus, Type 2 | Overweight or Obesity

China
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; Massachusetts General Hospital; University of Missouri-Columbia and other collaborators

Recruiting

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes (BESTMED)

Diabetes Mellitus, Type 2

United States
xiaolong zhao
Shanghai Zhongshan Hospital; Second Affiliated Hospital of Soochow University; Taizhou Hospital and other collaborators

Unknown

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy (T2DMRS)

Type 2 Diabetes

China
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Healthy | Type 2 Diabetes Mellitus

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute

Recruiting

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD)

Type2Diabetes | ASCVD

United States

Search clinical trials for: GLP-1 receptor agonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations